Phil B.FontanarosaMD, Deputy EditorIndividualAuthorMargaret A.WinkerMD, Deputy EditorIndividualAuthorStephen J.LurieMD, PhD, Fishbein FellowIndividualAuthor
Copyright 2000 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.2000
To the Editor: About 7% of breast cancers are
associated with a mutation of BRCA1 or BRCA2.1 Preventive management in
the population of women with genetically determined breast cancer is challenging
because there are limited data about strategies, efficacy, and risk-benefit
ratios. Women who test positive for a BRCA1 or BRCA2 mutation face difficult decisions about whether to
undergo prophylactic mastectomy. A substantial benefit of prophylactic mastectomy
was recently documented in women with a family history of breast cancer.2 However, from a public health point of view, the
impact of any treatment depends not only on efficacy but also on availability,
affordability, and acceptability of the procedure. On the assumption that
availability and affordability could be achieved, we investigated the acceptability
of the procedure.
Eisinger F, Julian-Reynier C, Sobol H, Stoppa-Lyonnet D, Lasset C, Nogues C. Philosophy. JAMA. 2000;283(2):202-203. doi:10-1001/pubs.JAMA-ISSN-0098-7484-283-2-jbk0112